» Articles » PMID: 28718307

Late Post-treatment Radiographic Changes 3 Years Following Chemoradiation for Glioma: the Importance of Histopathology

Overview
Journal CNS Oncol
Specialty Oncology
Date 2017 Jul 19
PMID 28718307
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment-related changes can mimic brain tumor progression both clinically and radiographically. Distinguishing these two entities represents a major challenge in neuro-oncology. No single imaging modality is capable of reliably achieving such distinction. While histopathology remains the gold standard, definitive pathological criteria are also lacking which can further complicate such cases. We report a patient with high-grade glioma who, after initially presenting with histopathologically confirmed pseudoprogression 10 months following treatment, re-presented 3 years following concurrent chemoradiation with clinical and radiographic changes that were most consistent with progressive disease but for which histopathology revealed treatment effects without active glioma. This case highlights the potential late onset of treatment-related changes and underscores the importance of histopathologic assessment even years following initial therapy.

Citing Articles

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.

Zeyen T, Paech D, Weller J, Schafer N, Tzaridis T, Duffy C J Neurooncol. 2023; 164(3):607-616.

PMID: 37728779 PMC: 10589172. DOI: 10.1007/s11060-023-04444-x.


Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.

Richter V, Klose U, Bender B, Rabehl K, Skardelly M, Schittenhelm J J Clin Med. 2021; 10(4).

PMID: 33562558 PMC: 7915936. DOI: 10.3390/jcm10040598.

References
1.
Li Y, Ballinger J, Nordal R, Su Z, Wong C . Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res. 2001; 61(8):3348-54. View

2.
Woodworth G, Garzon-Muvdi T, Ye X, Blakeley J, Weingart J, Burger P . Histopathological correlates with survival in reoperated glioblastomas. J Neurooncol. 2013; 113(3):485-93. PMC: 3994532. DOI: 10.1007/s11060-013-1141-3. View

3.
Parvez K, Parvez A, Zadeh G . The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci. 2014; 15(7):11832-46. PMC: 4139817. DOI: 10.3390/ijms150711832. View

4.
Shonka N, Theeler B, Cahill D, Yung A, Smith L, Lei X . Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol. 2013; 113(2):305-11. DOI: 10.1007/s11060-013-1116-4. View

5.
Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, Cognetti F . Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Res. 2009; 29(7):2607-10. View